Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford secures £7.8M funding to become Cancer Research UK’s joint largest Centre for training clinical academics.

None © Alistair Easton 'Multiplex IF image of skin biopsy'

Lead by Cancer Research UK Oxford Centre co-director Mark Middleton, this funding (for 8 DPhil studentships per year) galvanises Oxford’s position as one of the world’s leading Centres for the training of clinician scientists. With the additional funding the Centre will more than double its clinical DPhil intake for 2020, and for the first time allow medical undergraduates, in addition to clinical trainees, the opportunity to commit to a career in cancer research.

The successful Oxford team that included Dr. Catherine Swales (Oxford Medical School Director of Clinical Studies), Rob Gilbert (Director Of Medical Sciences Doctoral Training Centre), Chris Pugh (Oxford University Clinical Academic Graduate School Director), Denise Best (Oxford University Clinical Academic Graduate School Associate Director) and Chris Norbury (Medical School Deputy Director Of Pre-Clinical Studies) structured Oxford’s scheme to provide researchers:

  • The opportunity to receive research training in world leading laboratory environments across both the Medical Sciences and Mathematical, Physics and Life Sciences Divisions.
  • The ability to gain a working in-depth knowledge of the fundamentals of cancer biology and cancer patient care through advanced level seminars.
  • An environment that nurtures talent and offers a post award support programme that has historically meant Oxford students are 20 times more likely than the national average to develop an independent academic career.

This vision for training the next generation of cancer researchers will be delivered through the newly launched DPhil in Cancer Science Programme, a Medical Sciences Doctoral Training Centre. This new qualification is available to both clinician and non-clinicians, will have an annual intake of between 11 and 20 students per year, bring cancer and oncology training of DPhil students at Oxford into line with other diseases and help drive improvements in cancer patient care using Oxford research expertise in the near future.

Professor Mark Middleton, Cancer Research UK Oxford Centre Co-Director, said: 'We are tremendously grateful to Cancer Research UK and their donors for the confidence they have shown in enabling us to build a new training platform that will provide cancer research leaders of the future a unique and exciting first step into the field.'

Dr Karen Noble, Cancer Research UK Head of Research Careers, said: 'Clinical researchers play an important role in helping CRUK achieve its mission of seeing 3 in 4 people survive their cancer within the next 20 years. Through the funding to Oxford, the best people will be able to train in the best labs at the time in their career that best suits them. As well as support for clinical trainees, we are excited to be funding MB-DPhil training, which will enable aspiring clinician scientists to undertake a DPhil as part of their medical degree.'

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.